Sarepta Therapeutics (SRPT)

Apr 22, 2025, 8:30 AM EDT - 1 day ago

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

Apr 21, 2025, 6:03 PM EDT - 2 days ago

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 15, 2025, 8:30 AM EDT - 8 days ago

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

Apr 4, 2025, 8:55 AM EDT - 19 days ago

Sarepta halts three studies testing gene therapy for muscle disorder

Apr 4, 2025, 8:44 AM EDT - 19 days ago

Sarepta Therapeutics Provides Update on ELEVIDYS

Apr 3, 2025, 3:23 PM EDT - 20 days ago

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

Apr 3, 2025, 10:00 AM EDT - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Connect

Apr 2, 2025, 10:00 AM EDT - 21 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Reach Out

Apr 1, 2025, 10:00 AM EDT - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Shareholders to Learn More About the Investigation

Mar 31, 2025, 5:54 PM EDT - 23 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 2:25 PM EDT - 23 days ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SLDB TSHA XBI

Mar 31, 2025, 10:00 AM EDT - 23 days ago

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 30, 2025, 10:00 AM EDT - 24 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation

Mar 28, 2025, 10:00 AM EDT - 26 days ago

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 27, 2025, 10:00 AM EDT - 27 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Connect

Mar 26, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation

Mar 24, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect

Mar 23, 2025, 10:00 AM EDT - 4 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 21, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation

Mar 20, 2025, 1:55 PM EDT - 4 weeks ago

Sarepta: Should Investors Run For The Exit?

Mar 20, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation

Mar 19, 2025, 4:00 PM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out

Mar 18, 2025, 6:16 PM EDT - 5 weeks ago

Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Mar 18, 2025, 1:30 PM EDT - 5 weeks ago

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge

IVV SPLG SPXL SPY SSO UPRO VOO

Mar 18, 2025, 9:54 AM EDT - 5 weeks ago

Sarepta Therapeutics' stock falls after patient dies of liver failure

Mar 18, 2025, 9:29 AM EDT - 5 weeks ago

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Mar 18, 2025, 8:17 AM EDT - 5 weeks ago

Sarepta says patient dies after treatment with gene therapy

Mar 4, 2025, 8:15 AM EST - 7 weeks ago

Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness

Feb 28, 2025, 9:00 AM EST - 7 weeks ago

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

Feb 26, 2025, 11:48 PM EST - 7 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 2 months ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

Feb 18, 2025, 10:20 AM EST - 2 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Feb 14, 2025, 8:30 AM EST - 2 months ago

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

Feb 12, 2025, 8:30 AM EST - 2 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

Feb 10, 2025, 8:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

ARWR

Jan 27, 2025, 1:00 AM EST - 3 months ago

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

Jan 16, 2025, 1:23 PM EST - 3 months ago

Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely

Jan 13, 2025, 12:25 PM EST - 3 months ago

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

Jan 7, 2025, 11:19 AM EST - 3 months ago

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 3 months ago

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 20, 2024, 4:45 PM EST - 4 months ago

Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku

Dec 18, 2024, 8:30 AM EST - 4 months ago

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Nov 26, 2024, 7:00 AM EST - 5 months ago

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

ARWR

Nov 8, 2024, 3:02 PM EST - 5 months ago

Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step

Nov 7, 2024, 2:10 AM EST - 5 months ago

Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 6 months ago

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments

Oct 23, 2024, 8:30 AM EDT - 6 months ago

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

Oct 21, 2024, 9:01 AM EDT - 6 months ago

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

GEV BKV ESE GRDN